ArticleFrontiers in pediatrics2022

Impact of 11q Loss of Heterozygosity Status on the Response of High-Risk Neuroblastoma With MYCN Amplification to Neoadjuvant Chemotherapy.

Xian-Ying Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.